Breast Cancer Information Information Research

Digital Infrared Thermal Imaging In Medical Therapy

Digital technology now makes Digital Infrared Thermal Imaging available to all. There now is a completely safe test that can aid in diagnosis, treatment and monitoring with absolutely no risk or radiation exposure.

DITI, or digital infrared thermal imaging, is a noninvasive diagnostic test that allows a health practitioner to see and measure changes in skin surface temperature. An infrared scanning camera translates infrared radiation emitted from the skin surface and records them on a color monitor. This visual image graphically maps the body temperature and is referred to as a thermogram. The spectrum of colors indicates an increase or decrease in the amount of infrared radiation being emitted from the body surface. In healthy people, there is a symmetrical skin pattern which is consistent and reproducible for any individual.

DITI is highly sensitive and can therefore be used clinically to detect disease in the vascular, muscular, neural and skeletal systems. Medical DITI has been used extensively in human medicine in the United States, Europe and Asia for the past 20 years. Until now, bulky equipment has hindered its diagnostic and economic feasibility. Now, PC-based infrared technology designed specifically for clinical application has changed all this.

Clinical uses for DITI include, defining the extent of a lesion of which a diagnosis has previously been made (for example, vascular disease); localizing an abnormal area not previously identified, so further diagnostic tests can be performed (as in Irritable Bowel Syndrome); detecting early lesions before they are clinically evident (as in breast cancer or other breast diseases); and monitoring the healing process before a patient returns to work or training (as in workman's compensation claims).

Medical DITI is filling the gap in clinical diagnosis; X-ray, Computed Tomography, Ultrasound and Magnetic Resonance Imaging (MRI), are tests of anatomy or structure. DITI is unique in its capability to show physiological or functional changes and metabolic processes. It has also proven to be a very useful complementary procedure to other diagnostic procedures.

Unlike most diagnostic modalities DITI is non invasive. It is a very sensitive and reliable means of graphically mapping and displaying skin surface temperature. With DITI you can diagnosis, evaluate, monitor and document a large number of injuries and conditions, including soft tissue injuries and sensory/autonomic nerve fiber dysfunction. Medical DITI can offer considerable financial savings by avoiding the need for more expensive investigation for many patients. Medical DITI can graphically display the biased feeling of pain by accurately displaying the changes in skin surface temperature. Disease states commonly associated with pain include Reflex Sympathetic Dystrophy or RSD, Fibromyalgia and Rheumatoid arthritis.

Medical DITI can show a combined effect of the autonomic nervous system and the vascular system, down to capillary dysfunctions. The effects of these changes reveal an asymmetry in temperature distribution on the surface of the body. DITI is a monitor of thermal abnormalities present in a number of diseases and physical injuries. It is used as an aid for diagnosis and prognosis, as well as therapy follow up and rehabilitation monitoring, within clinical fields that include rheumatology, neurology, physiotherapy, sports medicine, oncology, pediatrics, orthopedics and many others.

Results obtained with medical DITI systems are totally objective and show excellent correlation with other diagnostic tests.

Thermographic screening is not covered by most insurance companies but is surprisingly affordable for most people. For more information or to find a certified clinic in your area, go to

Brenda Witt is co-owner of Proactive Health Solutions in Southern California. She is an American College of Clinical Thermology (ACCT) certified thermographer in the Orange County area.


Fox News

Disappointments for Roche in breast cancer, Alzheimer's drug trials
SFGate (blog)
Roche already has a best-selling breast cancer drug in Herceptin, but the patent will expire in five years. The Swiss pharmaceutical giant was hoping to secure its place in the market by expanding the group of possible patients eligible for Kadcyla and ...
UPDATE 3-Double blow for Roche as breast cancer, Alzheimer's studies failReuters
Double blow for Roche as Alzheimer's, breast cancer studies failFox News
ImmunoGen shares plunge after breast cancer drug falls short in large trialBoston Business Journal (blog)
Nasdaq -Yahoo News
all 88 news articles »


For Breast Cancer: It's Not Nature vs. Nurture—It's Both
Dean Ornish is Founder and President of the non-profit Preventive Medicine Research Institute and Clinical Professor of Medicine at UCSF. Genetics and lifestyle are both in play. In 2003, a mountain climber (Aron Ralston) became trapped under an 800 ...

and more »

Local surgeon attends SA breast cancer symposium
Herald Zeitung
Dr. Judith L. Thompson, a general surgeon with a special interest in the diagnosis and management of breast disease, has been a part of the New Braunfels medical community since 1996. Almost each year, she has attended the International Breast Cancer ...

Statin Cholesterol Drugs and Invasive Breast Cancer
What does breast cancer have to do with cholesterol? There are many potential mechanisms by which cholesterol boosts breast cancer growth. For example, our bodies make estrogen, which is correlated with increased risk of breast cancer, out of ...

and more »

The Raw Food World News

Really? Using a Metal-Detector for Breast Cancer
The Raw Food World News
(TRFW News) While not the type of metal-detector that guides you to buried treasures on the beach, future research is pointing to a type of metal locator that can detect breast cancer by measuring metal isotopes (1). What this is all about is that the ...

Ars Technica

Myriad's Breast Cancer Test Patents Not Patent Eligible
The National Law Review
Following a 2013 decision in which the Supreme Court invalidated Myriad Genetics, Inc.'s patents on human genes, the Federal Circuit this month went a step further, and held that Myriad's breast cancer test patents are also patent ineligible under ...
Myriad Loses Appeals Court Bid to Block Breast Cancer TestsBloomberg
Myriad Genetics (MYGN) Loses Gene Testing Patent Appeal To AmbryBidness ETC
Myriad Genetics loses gene patent appeal to AmbryU-T San Diego
Law360 (subscription)
all 26 news articles »

Drug Discovery & Development

Decreased weight, increased activity improved breast cancer survival for some ...
The Oncology Report
For women with tumors that are both estrogen and progesterone receptor negative, losing at least 5 pounds or 5% of total body weight decreased the 10-year risk of all-cause mortality by 64%, Dr. Rowan T. Chlebowski said at the San Antonio Breast Cancer ...
Combo Drug Therapy Doubles Positive Effect for Women with Breast CancerDrug Discovery & Development
Adding ovarian suppression to tamoxifen reduced recurrence for some ...Oncology Nurse Advisor
Celgene's (NASDAQ: CELG) Breast Cancer Drug Shows
Breast Cancer News -Cancer Network
all 20 news articles »

'Snail' gene gives breast cancer the ability to move
Futurity: Research News
A gene normally involved in the regulation of embryonic development allows breast cancer cells to break free and move through the body without regard to biological controls that normally restrict metastasis. The findings are important as more than 90 ...

Breast cancer prevention drug provides benefit long after women stop taking it
KANSAS CITY, Kan. — Breast cancer is the most common cancer in women. Yet fewer than one out of 10 women at higher risk take medication for prevention. New research finds one medicine continues to lower the chances of cancer long after women stop ...

and more »

Roche Drugs For Alzheimer's, Breast Cancer Disappoint BIIB LLY
Investor's Business Daily
Big Swiss pharma Roche (OTCPK:RHHBY) halted development of its Alzheimer's disease drug and reported mediocre results from a clinical trial of breast-cancer drug Kadcyla Friday, sending the stock down more than 6% in early trading on the stock market ...

Google News


home | site map
© 2006